|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FAM92A |
Gene summary for FAM92A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FAM92A | Gene ID | 137392 |
| Gene name | CBY1 interacting BAR domain containing 1 | |
| Gene Alias | BARMR1 | |
| Cytomap | 8q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0006996 | UniProtAcc | A1XBS5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 137392 | FAM92A | HCC2 | Human | Liver | HCC | 2.81e-07 | 2.79e+00 | 0.5341 |
| 137392 | FAM92A | S014 | Human | Liver | HCC | 2.16e-16 | 4.76e-01 | 0.2254 |
| 137392 | FAM92A | S015 | Human | Liver | HCC | 1.25e-24 | 9.81e-01 | 0.2375 |
| 137392 | FAM92A | S016 | Human | Liver | HCC | 1.81e-05 | 3.79e-01 | 0.2243 |
| 137392 | FAM92A | S027 | Human | Liver | HCC | 1.00e-18 | 1.10e+00 | 0.2446 |
| 137392 | FAM92A | S028 | Human | Liver | HCC | 9.31e-43 | 1.35e+00 | 0.2503 |
| 137392 | FAM92A | S029 | Human | Liver | HCC | 3.73e-36 | 1.43e+00 | 0.2581 |
| 137392 | FAM92A | male-WTA | Human | Thyroid | PTC | 5.95e-07 | 1.12e-01 | 0.1037 |
| 137392 | FAM92A | PTC01 | Human | Thyroid | PTC | 5.96e-08 | 1.46e-01 | 0.1899 |
| 137392 | FAM92A | PTC04 | Human | Thyroid | PTC | 5.14e-03 | 9.16e-02 | 0.1927 |
| 137392 | FAM92A | PTC05 | Human | Thyroid | PTC | 3.72e-10 | 3.16e-01 | 0.2065 |
| 137392 | FAM92A | PTC06 | Human | Thyroid | PTC | 3.41e-10 | 2.84e-01 | 0.2057 |
| 137392 | FAM92A | PTC07 | Human | Thyroid | PTC | 1.04e-12 | 2.96e-01 | 0.2044 |
| 137392 | FAM92A | ATC09 | Human | Thyroid | ATC | 1.29e-03 | 2.02e-01 | 0.2871 |
| 137392 | FAM92A | ATC12 | Human | Thyroid | ATC | 2.74e-06 | 1.86e-01 | 0.34 |
| 137392 | FAM92A | ATC13 | Human | Thyroid | ATC | 5.02e-78 | 1.43e+00 | 0.34 |
| 137392 | FAM92A | ATC1 | Human | Thyroid | ATC | 2.78e-04 | 2.35e-01 | 0.2878 |
| 137392 | FAM92A | ATC2 | Human | Thyroid | ATC | 3.71e-05 | 4.72e-01 | 0.34 |
| 137392 | FAM92A | ATC3 | Human | Thyroid | ATC | 6.22e-03 | 2.41e-01 | 0.338 |
| 137392 | FAM92A | ATC4 | Human | Thyroid | ATC | 4.56e-09 | 2.31e-01 | 0.34 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FAM92A | SNV | Missense_Mutation | c.404N>G | p.Gln135Arg | p.Q135R | A1XBS5 | protein_coding | deleterious(0.04) | probably_damaging(0.959) | TCGA-A8-A09K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| FAM92A | SNV | Missense_Mutation | novel | c.37N>C | p.Thr13Pro | p.T13P | A1XBS5 | protein_coding | deleterious(0.02) | probably_damaging(0.968) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FAM92A | SNV | Missense_Mutation | c.758G>T | p.Cys253Phe | p.C253F | A1XBS5 | protein_coding | tolerated(0.67) | benign(0.169) | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | |
| FAM92A | SNV | Missense_Mutation | c.355N>T | p.Ala119Ser | p.A119S | A1XBS5 | protein_coding | deleterious(0.05) | probably_damaging(0.98) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| FAM92A | SNV | Missense_Mutation | c.134N>T | p.Arg45Ile | p.R45I | A1XBS5 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| FAM92A | SNV | Missense_Mutation | novel | c.400N>T | p.Arg134Cys | p.R134C | A1XBS5 | protein_coding | tolerated(0.05) | benign(0.262) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FAM92A | SNV | Missense_Mutation | c.487C>T | p.Arg163Cys | p.R163C | A1XBS5 | protein_coding | tolerated(0.11) | benign(0.014) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| FAM92A | SNV | Missense_Mutation | rs201718859 | c.170N>T | p.Ala57Val | p.A57V | A1XBS5 | protein_coding | tolerated(0.37) | benign(0.001) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| FAM92A | SNV | Missense_Mutation | novel | c.283G>T | p.Val95Leu | p.V95L | A1XBS5 | protein_coding | deleterious(0.03) | possibly_damaging(0.629) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FAM92A | SNV | Missense_Mutation | novel | c.160N>A | p.Glu54Lys | p.E54K | A1XBS5 | protein_coding | deleterious(0.02) | possibly_damaging(0.688) | TCGA-AX-A2H2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |